Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15004608 | 0.82 | KMT2A (0.61) | KMT2AKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL266148 | 0.79 | KMT2A (0.58) | KMT2AKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL2820859 | 0.78 | KMT2A (0.53) | KMT2AKDM4EALDH1A1GAANPC1 | |
| SCHEMBL6479532 | 0.76 | KMT2A (0.54) | KMT2AKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL15004600 | 0.76 | NPC1 (0.58) | KMT2AKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL18901345 | 0.76 | KMT2A (0.54) | KMT2AKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL18304943 | 0.76 | KMT2A (0.54) | KMT2AKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL16563652 | 0.76 | KMT2A (0.54) | KMT2AKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL7965109 | 0.76 | KMT2A (0.54) | KMT2AKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL10424639 | 0.76 | KMT2A (0.59) | KMT2AKDM4EALDH1A1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2011137220-A1 | SMALL MOLECULE NEUROPEPTIDE S ANTAGONISTS FOR THE TREATMENT OF ADDICTIVE DISORDERS, MOOD, ANXIETY AND SLEEP DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-11-03 | — | — | WO | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010108074-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| WO-2009030952-A2 | PHENYLCARBOXAMIDE DERIVATIVES AS INHIBITORS AND EFFECTORS OF THE HEDGEHOG PATHWAY | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | WO | disclosed |
| EP-0556080-B1 | Bicyclic pyridine derivatives, process for their preparation, intermediates, their use as medicaments and pharmaceutical compositions containing them | AVENTIS PHARMA SA (FR) | 2002-05-08 | — | — | EP | disclosed |
| US-5691347-A | ANGIOTENSIN II INHIBITORS AND VASOCONSTRICTION | ROUSSEL UCLAF (FR) | 1997-11-25 | — | — | US | disclosed |
| US-5650414-A | PYRAZOLOPYRIDINES OR IMIDAZOLOPYRIDINES | ROUSSEL UCLAF (FR) | 1997-07-22 | — | — | US | disclosed |
| US-5420138-A | Antivasoconstriction compounds and cardiovascular disorders | ROUSSEL-UCLAF (FR) | 1995-05-30 | — | — | US | disclosed |
| EP-0556080-A1 | Bicyclic pyridine derivatives, process for their preparation, intermediates, their use as medicaments and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | KMT2A 2678/4885KDM4E 2683/4885ALDH1A1 3764/4885 |
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | KMT2A 2422/4885KDM4E 3143/4885ALDH1A1 4740/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | KMT2A 1139/4885KDM4E 1188/4885ALDH1A1 622/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | KMT2A 2422/4885KDM4E 3143/4885ALDH1A1 4740/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | KMT2A 2966/4885KDM4E 2802/4885ALDH1A1 2279/4885 |
| US-12215105-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | KMT2A 2422/4885KDM4E 3143/4885ALDH1A1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.